Min Hao
Impact in
- Molecular Medicine top 2%
- Antibiotic Resistance in Bacteria
- Curcumin's Biomedical Applications
-
- Traditional Chinese Medicine Analysis
Papers in
-
- Traditional Chinese Medicine Analysis 22
-
- Liver physiology and pathology 8
- Co-authors
- Xiaohua Qin (6 shared papers)Fupin Hu (5 shared papers)Lianlin Su (17 shared papers)De Ji (12 shared papers)Xiaogang Xu (4 shared papers)Shi Wu (4 shared papers)Xianan Sang (15 shared papers)Kuilong Wang (14 shared papers)
- Journals
- Frontiers in Pharmacology (6 papers)Journal of Ethnopharmacology (5 papers)Frontiers in Chemistry (3 papers)World Journal of Traditional Chinese Medicine (2 papers)International Journal of Antimicrobial Agents (2 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Min Hao
87 papers receiving 1.4k citations
Min Hao's Hit Papers
Peers
Comparison fields: 5 of 93
- Molecular Medicine 305
- Complementary and alternative medicine 225
- Pharmacology 72
- Drug Discovery 2
- Applied Microbiology and Biotechnology 15
Countries citing papers authored by Min Hao
This map shows the geographic impact of Min Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min Hao more than expected).
Fields of papers citing papers by Min Hao
This network shows the impact of papers produced by Min Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min Hao. The network helps show where Min Hao may publish in the future.
Co-authors
The 25 scholars most cited alongside Min Hao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 92 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 146 | |
| 2 | 2020 | 76 | |
| 3 | 2022 | 73 | |
| 4 | Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China Hit paper breakdown → | 2024 | 66 |
| 5 | 2024 | 64 | |
| 6 | 2021 | 62 | |
| 7 | 2019 | 46 | |
| 8 | 2020 | 45 | |
| 9 | 2009 | 41 | |
| 10 | 2018 | 35 | |
| 11 | 2019 | 35 | |
| 12 | 2020 | 33 | |
| 13 | 2022 | 32 | |
| 14 | 2018 | 30 | |
| 15 | 2021 | 30 | |
| 16 | 2011 | 28 | |
| 17 | 2017 | 25 | |
| 18 | 2024 | 23 | |
| 19 | 2021 | 22 | |
| 20 | 2021 | 22 |
About Min Hao
Min Hao is a scholar working on Complementary and alternative medicine, Hepatology, Molecular Medicine, Media Technology and Pharmacology, having authored 92 papers that have together received 1.5k indexed citations. Recurring topics across this work include Traditional Chinese Medicine Analysis (22 papers), Analog and Mixed-Signal Circuit Design (9 papers), Liver physiology and pathology (8 papers), Antibiotic Resistance in Bacteria (6 papers), Radio Frequency Integrated Circuit Design (5 papers), RFID technology advancements (5 papers), Plant-based Medicinal Research (4 papers) and Advancements in PLL and VCO Technologies (4 papers). The work is most often cited by research in Molecular Medicine (305 citations), Complementary and alternative medicine (225 citations), Pharmacology (72 citations), Drug Discovery (2 citations) and Applied Microbiology and Biotechnology (15 citations). Min Hao has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Xiaohua Qin, Fupin Hu, Lianlin Su, De Ji, Xiaogang Xu, Shi Wu, Xianan Sang, Kuilong Wang, Minggui Wang and Yang Yang. Their work appears in journals such as Frontiers in Pharmacology, Journal of Ethnopharmacology, Frontiers in Chemistry, World Journal of Traditional Chinese Medicine and International Journal of Antimicrobial Agents.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.